These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29632732)

  • 21. Local delivery of IL-2 reduces atherosclerosis via expansion of regulatory T cells.
    Dietrich T; Hucko T; Schneemann C; Neumann M; Menrad A; Willuda J; Atrott K; Stibenz D; Fleck E; Graf K; Menssen HD
    Atherosclerosis; 2012 Feb; 220(2):329-36. PubMed ID: 22062588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
    Pretto F; Elia G; Castioni N; Neri D
    Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response.
    Habets TH; Oth T; Houben AW; Huijskens MJ; Senden-Gijsbers BL; Schnijderberg MC; Brans B; Dubois LJ; Lambin P; De Saint-Hubert M; Germeraad WT; Tilanus MG; Mottaghy FM; Bos GM; Vanderlocht J
    PLoS One; 2016; 11(7):e0159515. PubMed ID: 27427766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.
    Golden EB; Chhabra A; Chachoua A; Adams S; Donach M; Fenton-Kerimian M; Friedman K; Ponzo F; Babb JS; Goldberg J; Demaria S; Formenti SC
    Lancet Oncol; 2015 Jul; 16(7):795-803. PubMed ID: 26095785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties
    Ongaro T; Gouyou B; Stringhini M; Corbellari R; Neri D; Villa A
    Oncotarget; 2020 Oct; 11(41):3698-3711. PubMed ID: 33110477
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
    Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM
    Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative evaluation of bolus and fractionated administration modalities for two antibody-cytokine fusions in immunocompetent tumor-bearing mice.
    Puca E; De Luca R; Seehusen F; Rodriguez JMM; Neri D
    J Control Release; 2020 Jan; 317():282-290. PubMed ID: 31790729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool's Gold or El Dorado?
    Xing D; Siva S; Hanna GG
    Clin Oncol (R Coll Radiol); 2019 Jul; 31(7):432-443. PubMed ID: 31005381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.
    Holden SA; Lan Y; Pardo AM; Wesolowski JS; Gillies SD
    Clin Cancer Res; 2001 Sep; 7(9):2862-9. PubMed ID: 11555604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models.
    El-Emir E; Dearling JL; Huhalov A; Robson MP; Boxer G; Neri D; van Dongen GA; Trachsel E; Begent RH; Pedley RB
    Br J Cancer; 2007 Jun; 96(12):1862-70. PubMed ID: 17519905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunocytokines are a promising immunotherapeutic approach against glioblastoma.
    Weiss T; Puca E; Silginer M; Hemmerle T; Pazahr S; Bink A; Weller M; Neri D; Roth P
    Sci Transl Med; 2020 Oct; 12(564):. PubMed ID: 33028706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-1 Restrains Radiotherapy-Induced Abscopal Effect.
    Park SS; Dong H; Liu X; Harrington SM; Krco CJ; Grams MP; Mansfield AS; Furutani KM; Olivier KR; Kwon ED
    Cancer Immunol Res; 2015 Jun; 3(6):610-9. PubMed ID: 25701325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combining Radiotherapy and Immunotherapy in Metastatic Breast Cancer: Current Status and Future Directions.
    David S; Tan J; Siva S; Karroum L; Savas P; Loi S
    Biomedicines; 2022 Mar; 10(4):. PubMed ID: 35453571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?
    Walshaw RC; Honeychurch J; Illidge TM
    Br J Radiol; 2016 Oct; 89(1066):20160472. PubMed ID: 27556933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8
    Hutmacher C; Gonzalo Núñez N; Liuzzi AR; Becher B; Neri D
    Cancer Immunol Res; 2019 Apr; 7(4):572-583. PubMed ID: 30782667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experimental model for the irradiation-mediated abscopal effect and factors influencing this effect.
    Baba K; Nomura M; Ohashi S; Hiratsuka T; Nakai Y; Saito T; Kondo Y; Fukuyama K; Kikuchi O; Yamada A; Matsubara J; Hirohashi K; Mitani Y; Mizumoto A; Muto M
    Am J Cancer Res; 2020; 10(2):440-453. PubMed ID: 32195019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia.
    Chi MS; Mehta MP; Yang KL; Lai HC; Lin YC; Ko HL; Wang YS; Liao KW; Chi KH
    Front Oncol; 2020; 10():254. PubMed ID: 32211319
    [No Abstract]   [Full Text] [Related]  

  • 38. The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.
    Catania C; Maur M; Berardi R; Rocca A; Giacomo AM; Spitaleri G; Masini C; Pierantoni C; González-Iglesias R; Zigon G; Tasciotti A; Giovannoni L; Lovato V; Elia G; Menssen HD; Neri D; Cascinu S; Conte PF; Braud Fd
    Cell Adh Migr; 2015; 9(1-2):14-21. PubMed ID: 25562532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer.
    Connor JP; Felder M; Hank J; Harter J; Gan J; Gillies SD; Sondel P
    J Immunother; 2004; 27(3):211-9. PubMed ID: 15076138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma.
    Wieckowski S; Hemmerle T; Prince SS; Schlienger BD; Hillinger S; Neri D; Zippelius A
    Lung Cancer; 2015 Apr; 88(1):9-15. PubMed ID: 25682318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.